Studies a blood marker of insulin-producing cell health in children with obesity
Looks at a blood marker in children with obesity, with or without diabetes.
Plain-language title generated from the registry record
Registry title: Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
Key facts
- Where
- Geneva, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 16 years old?
Source: NCT06682481, who can take part
Where in Switzerland
- University Hospital of GenevaGeneva, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Philippe Klee, MD-PhD
- Trial code
- NCT06682481
- Record updated
- 18 May 2026
- Original description
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.Read full original descriptionShow less
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.
Inclusion: Children aged 12 to 16 years; Obesity. Defined as a body-mass index above the 97th percentile; Ability to give informed consent as documented by signature.
Exclusion: Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion; Patients treated with a drug known to affect liver function; Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8; Patients with known liver disease (other than NAFLD).